About Santarus
Santarus is a Healthcare company based in San Diego (United States) founded in 1996, and was acquired by Salix Pharmaceuticals in November 2013. Proprietary biopharmaceutical products for gastrointestinal and metabolic conditions are commercialized. Santarus has raised $51.4 million across 1 funding round from investors including Salix Pharmaceuticals, Life Sciences Partners and SR One. Its focus areas include Diversified Pharmaceuticals.
Company details
Santarus was founded in 1996 in San Diego, United States, as a specialty biopharmaceutical company. Proprietary products are acquired, developed, and commercialized, primarily targeting gastrointestinal diseases. The portfolio encompasses Uceris for ulcerative colitis treatment and Zegerid for stomach acid reduction. Additional offerings include Glumetza and Cycloset for Type 2 diabetes management, as well as Fenoglide for high cholesterol control.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website santarus.com
- Social LinkedIn
- Acquired by Salix Pharmaceuticals (Nov 2013)
- Total Equity Funding$51.4M (USD)
in 1 rounds
- Latest Funding Round$51.4M (USD), Series D
May 2003
- InvestorsSalix Pharmaceuticals
& 9 more
- Acquired bySalix Pharmaceuticals
(Nov 2013)
Funding Insights of Santarus
Santarus has successfully raised a total of $51.4M through 1 strategic funding round. The most recent funding activity was a Series D round of $51.4 million completed in May 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.4M
- Total Rounds 1
- Last Round Series D — $51.4M
- First Round $51.4M
(May 2003)
- Investors Count 9
All 1 funding rounds of Santarus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2003 | $51.4M | Series D | – | SR One |
10 investors in total: 10 institutional.
Investors in Santarus
Santarus has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Salix Pharmaceuticals, Life Sciences Partners and SR One.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
| hamiltonapex.com | ||||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Private equity investments are directed toward multiple sectors. | ccmpcapital.com | New York, United States | ||
Life Sciences & Offline focused early stage VC firm investing in the US | windamerevp.com | San Diego, United States | ||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
| nepartners.com | ||||
| cdibbiosciencevc.com | ||||
Specialty pharmaceutical company focusing on prevention and treatment of gastrointestinal (GI) disorders. | 1989 | salix.com | Bridgewater, United States |
Investor details for Santarus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Santarus
2 people are tracked at Santarus (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Grace Benedict | Director Of Pharmaceutical Sciences | Leadership |
Ralph Clevinger | Regional Account Manager | Team |
Complete people profiles for Santarus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Santarus
4 dated milestones of Santarus across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Santarus is founded.
- Funding First funding round of $51.4M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Salix Pharmaceuticals.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Santarus (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Santarus
Santarus was founded in 1996 and raised its 1st funding round 7 years after it was founded.
Santarus is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Santarus is a funded company, having raised a total of $51.4M across 1 funding round to date. The company's 1st funding round was a Series D of $51.4M, raised on May 2003.
Santarus was founded in 1996 in San Diego, United States, as a specialty biopharmaceutical company. Proprietary products are acquired, developed, and commercialized, primarily targeting gastrointestinal diseases. The portfolio encompasses Uceris for ulcerative colitis treatment and Zegerid for stomach acid reduction. Additional offerings include Glumetza and Cycloset for Type 2 diabetes management, as well as Fenoglide for high cholesterol control.
Santarus has 10 investors. Key investors include Salix Pharmaceuticals, Life Sciences Partners, SR One, Hamilton Apex, and New England Partners Capital.
Yes. Santarus was acquired by Salix Pharmaceuticals in November 2013.